Phase I Study in Healthy Women of a Novel Antimycotic Vaginal Ovule Combining Econazole and Benzydamine

Purpose. A novel fixed-dose combination of 150 mg of econazole with 6 mg of benzydamine formulated in vaginal ovules was investigated in a randomised, double-blind, four-parallel group, tolerability, and pharmacokinetic Phase I study in healthy women. Methods. The fixed-dose combination was compared...

Full description

Bibliographic Details
Main Authors: A. F. D. Di Stefano, M. M. Radicioni, A. Vaccani, G. Caccia, F. Focanti, E. Salvatori, F. Pelacchi, R. Picollo, M. T. Rosignoli, S. Olivieri, G. Bovi, A. Comandini
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Infectious Diseases in Obstetrics and Gynecology
Online Access:http://dx.doi.org/10.1155/2020/7201840
id doaj-3c1c68baad9749f29151aebdaa2ba5fa
record_format Article
spelling doaj-3c1c68baad9749f29151aebdaa2ba5fa2020-11-25T03:04:38ZengHindawi LimitedInfectious Diseases in Obstetrics and Gynecology1064-74491098-09972020-01-01202010.1155/2020/72018407201840Phase I Study in Healthy Women of a Novel Antimycotic Vaginal Ovule Combining Econazole and BenzydamineA. F. D. Di Stefano0M. M. Radicioni1A. Vaccani2G. Caccia3F. Focanti4E. Salvatori5F. Pelacchi6R. Picollo7M. T. Rosignoli8S. Olivieri9G. Bovi10A. Comandini11CROSS Research S.A., Via F. A. Giorgioli, 14, CH-6864 Arzo, SwitzerlandCROSS Research S.A., Via F. A. Giorgioli, 14, CH-6864 Arzo, SwitzerlandCROSS Research S.A., Via F. A. Giorgioli, 14, CH-6864 Arzo, SwitzerlandService for Gynaecology and Obstetrics, Ospedale Regionale di Mendrisio, Mendrisio, SwitzerlandAngelini S.p.A., S. Palomba, Rome, ItalyAngelini S.p.A., S. Palomba, Rome, ItalyAngelini S.p.A., S. Palomba, Rome, ItalyAngelini S.p.A., S. Palomba, Rome, ItalyAngelini S.p.A., S. Palomba, Rome, ItalyAngelini S.p.A., S. Palomba, Rome, ItalyAngelini S.p.A., S. Palomba, Rome, ItalyAngelini S.p.A., S. Palomba, Rome, ItalyPurpose. A novel fixed-dose combination of 150 mg of econazole with 6 mg of benzydamine formulated in vaginal ovules was investigated in a randomised, double-blind, four-parallel group, tolerability, and pharmacokinetic Phase I study in healthy women. Methods. The fixed-dose combination was compared to econazole and benzydamine single-drug formulations and with placebo after daily applications for 3 consecutive days. Safety and tolerability were evaluated recording the adverse drug reactions, local and general tolerability scores, clinical laboratory assays, and vital signs. Econazole, benzydamine, and its metabolite benzydamine N-oxide pharmacokinetics were investigated after single and multiple applications. Results. Local reactions were generally absent. Pruritus and pain at the application site were infrequently reported. According to the subjects’ evaluations, the overall tolerability of the ovules was rated as excellent or good. No significant effect of any treatment on laboratory parameters, vital signs, body weight, vaginal pH, or ECG was observed. Very low econazole, benzydamine, and benzydamine-N-oxide concentrations were measured in plasma, though quantifiable in almost all samples. Conclusion. The tested fixed-dose combination showed a good safety profile consistently with the known tolerability of both active substances. In addition, the confirmed low bioavailability of the drugs excludes the possibility of any accumulation effects and limits the risk of undesired systemic effects. This trial is registered at ClinicalTrials.gov with the identifier NCT02720783 last updated on 07 February 2017.http://dx.doi.org/10.1155/2020/7201840
collection DOAJ
language English
format Article
sources DOAJ
author A. F. D. Di Stefano
M. M. Radicioni
A. Vaccani
G. Caccia
F. Focanti
E. Salvatori
F. Pelacchi
R. Picollo
M. T. Rosignoli
S. Olivieri
G. Bovi
A. Comandini
spellingShingle A. F. D. Di Stefano
M. M. Radicioni
A. Vaccani
G. Caccia
F. Focanti
E. Salvatori
F. Pelacchi
R. Picollo
M. T. Rosignoli
S. Olivieri
G. Bovi
A. Comandini
Phase I Study in Healthy Women of a Novel Antimycotic Vaginal Ovule Combining Econazole and Benzydamine
Infectious Diseases in Obstetrics and Gynecology
author_facet A. F. D. Di Stefano
M. M. Radicioni
A. Vaccani
G. Caccia
F. Focanti
E. Salvatori
F. Pelacchi
R. Picollo
M. T. Rosignoli
S. Olivieri
G. Bovi
A. Comandini
author_sort A. F. D. Di Stefano
title Phase I Study in Healthy Women of a Novel Antimycotic Vaginal Ovule Combining Econazole and Benzydamine
title_short Phase I Study in Healthy Women of a Novel Antimycotic Vaginal Ovule Combining Econazole and Benzydamine
title_full Phase I Study in Healthy Women of a Novel Antimycotic Vaginal Ovule Combining Econazole and Benzydamine
title_fullStr Phase I Study in Healthy Women of a Novel Antimycotic Vaginal Ovule Combining Econazole and Benzydamine
title_full_unstemmed Phase I Study in Healthy Women of a Novel Antimycotic Vaginal Ovule Combining Econazole and Benzydamine
title_sort phase i study in healthy women of a novel antimycotic vaginal ovule combining econazole and benzydamine
publisher Hindawi Limited
series Infectious Diseases in Obstetrics and Gynecology
issn 1064-7449
1098-0997
publishDate 2020-01-01
description Purpose. A novel fixed-dose combination of 150 mg of econazole with 6 mg of benzydamine formulated in vaginal ovules was investigated in a randomised, double-blind, four-parallel group, tolerability, and pharmacokinetic Phase I study in healthy women. Methods. The fixed-dose combination was compared to econazole and benzydamine single-drug formulations and with placebo after daily applications for 3 consecutive days. Safety and tolerability were evaluated recording the adverse drug reactions, local and general tolerability scores, clinical laboratory assays, and vital signs. Econazole, benzydamine, and its metabolite benzydamine N-oxide pharmacokinetics were investigated after single and multiple applications. Results. Local reactions were generally absent. Pruritus and pain at the application site were infrequently reported. According to the subjects’ evaluations, the overall tolerability of the ovules was rated as excellent or good. No significant effect of any treatment on laboratory parameters, vital signs, body weight, vaginal pH, or ECG was observed. Very low econazole, benzydamine, and benzydamine-N-oxide concentrations were measured in plasma, though quantifiable in almost all samples. Conclusion. The tested fixed-dose combination showed a good safety profile consistently with the known tolerability of both active substances. In addition, the confirmed low bioavailability of the drugs excludes the possibility of any accumulation effects and limits the risk of undesired systemic effects. This trial is registered at ClinicalTrials.gov with the identifier NCT02720783 last updated on 07 February 2017.
url http://dx.doi.org/10.1155/2020/7201840
work_keys_str_mv AT afddistefano phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT mmradicioni phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT avaccani phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT gcaccia phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT ffocanti phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT esalvatori phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT fpelacchi phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT rpicollo phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT mtrosignoli phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT solivieri phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT gbovi phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
AT acomandini phaseistudyinhealthywomenofanovelantimycoticvaginalovulecombiningeconazoleandbenzydamine
_version_ 1715311465566568448